A key challenge in studying native GLP-1 is its extremely short in vivo half-life of approximately 12 minutes, owing to rapid inactivation by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide from GLP-1 to produce the inactive metabolite GLP-1(936)amide
Gogineni P, Melson E, Papamargaritis D, Davies M
K., Chien, M
*P.B.s Medicare Part D plan for medications wont cover Mounjaro due to a federal law passed in 2003 that prohibited Medicare from covering weight management medications because of supposed dangerous side effects
the cohort included 13,204 GLP-1 RA users and 13,204 nonusers.The researchers observed associations for GLP-1 RA use with lower risks for stroke/transient ischemic attack, pulmonary embolism, venous thromboembolism, emergency department visits, and mortality (hazard ratios, 0.87, 0.69, 0.83, 0.79, and 0.56, respectively)."As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically -- that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients," Fatima Cody Stanford, M.D., M.P.H., member of the American Heart Association Lifestyle and Cardiometabolic Council, said in a statement.Abstract/Full TextMore Information.Sign up for our weekly HealthDay newsletter
